


I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 596703554 US, on the date shown below in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: October 19, 2006

Signature:


(Lori Sims)

Patent
Docket No. 475512000400

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Steven M. WATKINS

Serial No.: 10/808,880

Filing Date: March 24, 2004

For: METHODS OF USING
QUANTITATIVE LIPID
METABOLOME DATA

Confirmation No.: 7468

Group Art Unit: 1651

Examiner: S. Saucier

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicant submits for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

This Supplemental Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of ___ is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of ___ is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicant would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.


The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 475512000400.

Dated: October 19, 2006

Respectfully submitted,

By


Alicia J. Hager
Registration No.: 44,140

MORRISON & FOERSTER LLP
755 Page Mill Road
Palo Alto, California 94304-1018
(650) 813-4296



ALTERNATIVE TO PTO/SB/08a/b (07-05)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/808,880
				Filing Date	March 24, 2004
				First Named Inventor	Steven M. WATKINS
				Art Unit	1651
				Examiner Name	S. Saucier
Sheet	1	of	2	Attorney Docket Number	475512000400

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			
	1.	WO-03/005628-A2,A3	01-16-2003	Lipomics Technologies, Inc.		
	2.	WO-03/028271-A2,A3	04-03-2003	Lipomics Technologies, Inc.		

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal al, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	3.	Aarsland, A. et al. (1998). "Hepatic Secretion of VLDL Fatty Acids During Stimulated Lipogenesis in Men," <i>Journal of Lipid Research</i> 39:1280-1286.		
	4.	Boersma, M.G. et al. (January 2001). "19F NMR Metabolomics for the Elucidation of Microbial Degradation Pathways of Flourophenols," <i>Ind. Microbial. Biotechnol.</i> 26(1/2):22-34.		
	5.	European Search Report mailed on August 9, 2006 for EP Patent Application No. 02782079.4, three pages.		
	6.	Griffin, J.L. et al. (June 1, 2001). "Metabolic Profiling of Genetic Disorders: A Multitissue ¹ H Nuclear Magnetic Resonance Spectroscopic and Pattern Recognition Study into Dystrophic Tissue," <i>Anal. Biochem.</i> 293(1):16-21.		
	7.	Jardine, A. et al. (December 1999). "Fluvastatin in Combination with Cyclosporin in Renal Transplant Recipients: A Review of Clinical and Safety Experience," <i>J. Clinical Pharmacy and Therapeutics</i> 24(6):397-408.		
	8.	Koletzko, B. et al. (1991). "Fatty Acid Composition of Mature Human Milk in Nigeria," <i>Zeitschrift Fur Ernahrungswissenschaft</i> 30(4):289-297.		
	9.	Lithell, H. (1993). "Hypertension and Hyperlipidema: A Review," <i>Am. J. of Hypertension</i> 6(11):303S-308S.		
	10.	Madsen, A. et al. (1992). "Influence of Dietary Fat of Carcass Fat Quality in Pigs: A Review," <i>Acta Agriculturae Scandinavica</i> 42(4):220-225.		
	11.	Romo, G. A. et al. (November 2000). "Milk Composition and Apparent Digestibilities of Dietary Fatty Acids in Lactating Dairy Cows Abomasally Infused With Cis or Trans Fatty Acids," <i>Journal of Dairy Science</i> 83(11):2609-2619.		
	12.	Saudek, C.D. et al. (May 1979). "Lipid Metabolism in Diabetes Mellitus," <i>Am. J. Med.</i> 66(5):843-852.		
	13.	Siguel, E.N. et al. (July 1987). "Relative Activity of Unsaturated Fatty Acid Metabolic Pathways in Humans," <i>Metabolism</i> 36(7):664-669.		
	14.	Siguel, E.N. et al. (September 1986). "Monitoring the Optimal Infusion of Intravenous Lipids. Detection of Essential Fatty Acid Deficiency," <i>Arch. Pathol. Lab. Med.</i> 110(9):792-797.		
	15.	Tanaka, K. et al. (April 30, 1982). "Compilation of Gas Chromatographic Retention Indices of 163 Metabolically Important Organic Acids and Their Use in Detection of Patients with Organic		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

pa-1104663

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/808,880
				Filing Date	March 24, 2004
				First Named Inventor	Steven M. WATKINS
				Art Unit	1651
				Examiner Name	S. Saucier
Sheet	2	of	2	Attorney Docket Number	475512000400

		Acidurias," <i>J. Chromatogr.</i> 239:301-322.	
	16.	Tate, A.R. et al. (May-June 1996). "Lipid Metabolite Peaks in Pattern Recognition Analysis of Tumour in Vivo MR Spectra," <i>Anticancer Res.</i> 16(3B):1575-1579.	
	17.	Tweeddale, H. et al. (October 1998). "Effect of Slow Growth of Metabolism of <i>Escherichia coli</i> , as Revealed by Global Metabolite Pool ("Metabolome") Analysis," <i>J. Bacteriol.</i> 180(19):5109-5116.	
	18.	Vigneau-Callahan, K.E. et al. (March 2001). "Characterization of Diet-Dependent Metabolic Serotypes: Analytical and Biological Variability Issues in Rats," <i>J. Nutr.</i> 131(3):924S-932S.	
	19.	Waters, N.J. et al. (July 1, 2002). "NMR and Pattern Recognition Studies on Liver Extracts and Intact Livers for Rats Treated with Alpha-Naphthylisocyanate," <i>Biochem. Pharm.</i> 64(1):67-77.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

pa- 1104663